NASDAQ
11.42USD
+0.43 (+3.91%)
We have scored 7 news catalysts on Kailera Therapeutics, Inc. (KLRA) over the past 12 months. The biggest single-day move next to one of them came Oct 1, 2026, when KLRA closed +3.9%: “Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting”. Coverage across the window leans positive (average ticker sentiment +0.64). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.5B
P/E
—
EPS
—
Beta
0.50
52W range
10.83-28.23
Day range
10.86–11.66
Open
11.16
Prev close
10.99
Volume
1.4M
Avg volume
836K
Dividend
0.00
IPO
2026-04-17
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Kailera Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KLRA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
